Unknown

Dataset Information

0

Healthcare value of implementing hepatitis C screening in the adult general population in Spain.


ABSTRACT:

Background

Elimination of hepatitis C virus (HCV) infection requires high diagnostic rates and universal access to treatment. Around 40% of infected individuals are unaware of their infection, which indicates that effective screening strategies are needed. We analyzed the efficiency (incremental cost-utility ratio, ICUR) of 3 HCV screening strategies: a) general population of adults, b) high-risk groups, and c) population with the highest anti-HCV prevalence plus high-risk groups.

Methods

An analytical decision model, projecting progression of the disease over a lifetime, was used to establish the candidate population for HCV screening. HCV data were obtained from the literature: anti-HCV prevalence (0.56%-1.54%), viremic patients (31.5%), and percentage of undiagnosed persons among those with viremia (35%). It was assumed that most patients would be treated and have HCV therapy response (98% SVR); transition probabilities, utilities, and disease management annual costs were obtained from the literature. Efficiency over the life of patients under the National Health System perspective was measured as quality-adjusted life years (QALY) and total cost (screening, diagnosis, pharmacological and disease management). A discount rate of 3% was applied to costs and outcomes.

Results

Screening of the adult population would identify a larger number of additional chronic hepatitis C cases (N = 52,694) than screening the highest anti-HCV prevalence population plus high-risk groups (N = 42,027) or screening high-risk groups (N = 26,128). ICUR for the general population vs. high-risk groups was €8914/QALY gained per patient (€18,157 incremental cost and 2.037 QALY). ICUR for the general population vs. population with highest anti-HCV prevalence plus high-risk groups was €7,448/QALY gained per patient (€7,733 incremental cost and 1.038 QALY). These ICUR values are below the accepted efficiency threshold (€22,000-€30,000).

Conclusion

HCV screening and treatment of the general adult population is cost-effective compared to screening of high-risk groups or the population with the highest anti-HCV prevalence plus high-risk groups.

SUBMITTER: Buti M 

PROVIDER: S-EPMC6261617 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature

altmetric image

Publications

Healthcare value of implementing hepatitis C screening in the adult general population in Spain.

Buti María M   Domínguez-Hernández Raquel R   Casado Miguel Ángel MÁ   Sabater Eliazar E   Esteban Rafael R  

PloS one 20181128 11


<h4>Background</h4>Elimination of hepatitis C virus (HCV) infection requires high diagnostic rates and universal access to treatment. Around 40% of infected individuals are unaware of their infection, which indicates that effective screening strategies are needed. We analyzed the efficiency (incremental cost-utility ratio, ICUR) of 3 HCV screening strategies: a) general population of adults, b) high-risk groups, and c) population with the highest anti-HCV prevalence plus high-risk groups.<h4>Met  ...[more]

Similar Datasets

| S-EPMC7327007 | biostudies-literature
| S-EPMC8531478 | biostudies-literature
| S-EPMC8514804 | biostudies-literature
| S-EPMC7757496 | biostudies-literature
| S-EPMC4016146 | biostudies-literature
| S-EPMC2394525 | biostudies-literature
| S-EPMC7925988 | biostudies-literature
| S-EPMC10230887 | biostudies-literature
| S-EPMC4689975 | biostudies-literature